Measles virus: A future therapeutic agent in oncology?;Le virus de la rougeole: Un futur traitement en cancérologie?

Medecine/Sciences

Volumn 28, Issue 4, 2012, Pages 388-394

  Touchefeu, Yann ^a,b   Schick, Ulrike ^a   Harrington, Kevin J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; ONCOLYTIC VIRUS;

ANIMAL; BIOLOGICAL MODEL; ENZYME SPECIFICITY; EVALUATION; HUMAN; IMMUNOLOGY; MEASLES VIRUS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASM; ONCOLOGY; ONCOLYTIC VIROTHERAPY; PATHOGENICITY; PHYSIOLOGY; REVIEW;

ANIMALS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MEASLES VIRUS; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SUBSTRATE SPECIFICITY;

MEASLES VIRUS;

EID: 84860870216     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/2012284016     Document Type: Review

References (41)

1. Global measles mortality, 2000-2008. Morb Mortal Wkly Rep 2009;58:1321-6.
2. Enders JF, Peebles TC. Propagation in tissue cul tures of cytopathogenic agents from patients with measles. Proc Soc Exp Biol Med 1954;86:277-86.
3. Muhlebach MD, Mateo M, Sinn PL, et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 2011;480:530-3.
4. Noyce RS, Bondre DG, Ha MN, et al. Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog 2011;7:e1002240.
5. Bluming AZ, Ziegler JL. Regression of Burkitt's lymphoma in association with measles infection. Lancet 1971;2:105-6.
6. Mota HC. Infantile Hodgkin' s disease: remission after measles. Br Med J 1973;2:421.
7. Taqi AM, Abdurrahman MB, Yakubu AM, Fleming AF. Regression of Hod gkin's disease after measles. Lancet 1981;1:1112.
8. Zygiert Z. Hodgkin's disease: rem issions after measles. Lancet 1971;1:593.
9. Heinzerling L, Kunzi V, Oberholzer PA, et al. Oncolytic measles virus in cu taneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood 2005;106:2287-94. (Pubitemid 41510798)
10. Galanis E, Hartmann LC, Cliby WA, et al. Phase I Trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 2010;70:875-82.
11. Dhiman N, Jacobson RM, Poland GA. Measles virus receptors: SLAM and CD46. Rev Med Virol 2004;14:217-29. (Pubitemid 38879814)
12. Dorig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a recepto r for measles virus (Edmonston strain). Cell 1993;75:295-305. (Pubitemid 23320293)
13. Anderson BD, Nakamura T, Russell SJ, Peng KW. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 2004;64:4919-26. (Pubitemid 38924538)
14. Bossow S, Gro ssardt C, Temme A, et al. Armed and targeted measles virus for chemovirotherapy of pancreatic cancer. Cancer Gene Ther 2011;18:598-608.
15. Ungerechts G, Springfeld C, Frenzke ME, et al. An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther 2007;15:1991-7. (Pubitemid 350011739)
16. Ungerechts G, Springfeld C, Frenzke ME, et al. Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res 2007;67:10939-47. (Pubitemid 350145923)
17. Allen C, Vong punsawad S, Nakamura T, et al. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res 2006;66:11840-50. (Pubitemid 46094196)
18. Allen C, Paraskevakou G, Liu C, et al. Oncolytic measles virus strains in the treatment of gliomas. Expert Opin Biol Ther 2008;8:213-20. (Pubitemid 351233714)
19. Liu C, Hasegawa K, Russell SJ, et al. Prostate-specific membrane a ntigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate 2009;69:1128-41.
20. Springfeld C, von Messling V, Frenzke M, et al. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res 2006;66:7694-700. (Pubitemid 44289228)
21. Leber MF, Bossow S, Leonard VH, et al. MicroRNA-sensitive oncolytic measles viruses for cancerspecific vector tropism. Mol Ther 2011;19:1097-106.
22. Morfin F, Beguin A, Lina B, Thouvenot D. Detection of measles vac cine in the throat of a vaccinated child. Vaccine 2002;20:1541-3. (Pubitemid 34169793)
23. Leonard VH, Sinn PL, Hodge G, et al. Measles virus blind to its epithelial cell rece ptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed. J Clin Invest 2008;118:2448-58. (Pubitemid 351949773)
24. Iankov ID, Blechacz B, Liu C, et al. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther 2007;15:114-22. (Pubitemid 46043656)
25. Mader EK, Maeyama Y, Lin Y, et al. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res 2009;15:7246-55.
26. Liu C, Russell SJ, Peng KW. Syste mic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther 2010;18:1155-64.
27. Lamfers ML, Fulci G, Gianni D, et al. Cyclophosphamide increases transgene expression m ediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol Ther 2006;14:779-88. (Pubitemid 44743132)
28. Myers RM, Greiner SM, Harvey ME, et al. Preclini cal pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 2007;82:700-10. (Pubitemid 350114828)
29. Bitnun A, Shannon P, Durward A, et al. Measles inclus ion-body encephalitis caused by the vaccine strain of measles virus. Clin Infect Dis 1999;29:855-61. (Pubitemid 30256382)
30. Miest TS, Yaiw KC, Frenzke M, et al. Envelope-chimeric entry-targeted measles virus escapes neutralization and achi eves oncolysis. Mol Ther 2011;19:1813-20.
31. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, sec ondgeneration oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009;27:5763-71.
32. Park BH, Hwang T, Liu TC, et al. Use of a targeted onco lytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008;9:533-42.
33. Ottolino-Perry K, Diallo JS, Lichty BD, et al. Intelligent design: combination therapy with oncolytic viruses. Mol Ther 2010;18:251-63.
34. Ungerechts G, Frenzke ME, Yaiw KC, et al. Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics. Gene Ther 2010;17:1506-16.
35. Touchef eu Y, Vassaux G, Harrington KJ. Oncolytic viruses in radiation oncology. Radiother Oncol 2011;99:262-70.
36. Liu C, Sarkaria JN, Petell CA, et al. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin Cancer Res 2007;13:7155-65. (Pubitemid 350276902)
37. Dingli D, Peng KW, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004;103:1641-6. (Pubitemid 38268954)
38. Msaouel P, Iankov ID, Allen C, et al. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium io dide symporter. Mol Ther 2009;17:2041-8.
39. Penheiter AR, Wegman TR, Classic KL, et al. Sodium iodide symporter (NIS) - mediated radiovirotherapy for pancreatic cancer. Am J Roentgenol 2010;195:341-9.
40. Mateo M, Lopez M. Nectine-4, une protéine clé pour la transmission du virus de la rougeole. Med Sci (Paris) 2012;28:363-5.
41. Lemay G. Apprivoiser nos ennemis pour en faire des alliés: la virothér apie anticancéreuse. Med Sci (Paris) 2012;28:339-40.